1. Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
   Susumu Takeuchi et al, 2023, Cancer Medicine CrossRef
2. Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study
   Tomoyuki Araya et al, 2019, Canadian Respiratory Journal CrossRef
3. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease
   Masaki Hanibuchi et al, 2018, Lung Cancer CrossRef
4. Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer
   Takeru Kashiwada et al, 2019, Japanese Journal of Clinical Oncology CrossRef
5. Pemetrexed
   , 2017, Reactions Weekly CrossRef
6. Anticancer drug treatment for advanced lung cancer with interstitial lung disease
   Kohei Otsubo et al, 2018, Respiratory Investigation CrossRef
7. A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)
   Hiroyuki Sakashita et al, 2022, Thoracic Cancer CrossRef
8. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias
   Tetsuo Fujita et al, 2018, Internal Medicine CrossRef
9. Randomized Phase II Trial of Standard Versus Low-Dose Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: JMTO LC14-01
   Susumu Takeuchi et al, SSRN Electronic Journal CrossRef
10. Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
    Yanning Wang et al, 2022, Frontiers in Oncology CrossRef
11. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)
    Hajime Asahina et al, 2019, Lung Cancer CrossRef
12. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence
    Diego Adrianzen Herrera et al, 2019, Expert Opinion on Pharmacotherapy CrossRef
13. Efficacy and safety of second‐line chemotherapy for patients with advanced non‐small cell lung cancer complicated by interstitial lung disease
    Kenji Otsuka et al, 2022, Thoracic Cancer CrossRef
14. The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis
    Yanning Wang et al, 2020, Frontiers in Oncology CrossRef
15. Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease
    Hirotsugu Kenmotsu et al, 2019, Cancer Science CrossRef
16. Treatment Strategy for Advanced Non-small-cell Lung Cancer with Interstitial Lung Disease
    Hiroshi Nokihara et al, 2020, Haigan CrossRef
17. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway
    Fu Xiaomeng et al, 2020, Brazilian Journal of Medical and Biological Research CrossRef